Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer
Authors
Keywords
Peritoneal Lavage, Epithelial Ovarian Carcinoma, CD137 Activation, Mean Survival Time, Ovarian Cancer Immunotherapy
Journal
Journal of Translational Medicine
Volume 11, Issue 1, Pages 215
Publisher
Springer Nature
Online
2013-09-17
DOI
10.1186/1479-5876-11-215
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Long-lasting Complete Regression of Established Mouse Tumors by Counteracting Th2 Inflammation
- (2013) Min Dai et al. JOURNAL OF IMMUNOTHERAPY
- Advances in targeting cell surface signalling molecules for immune modulation
- (2013) Sheng Yao et al. NATURE REVIEWS DRUG DISCOVERY
- TIM-3 Does Not Act as a Receptor for Galectin-9
- (2013) Judith Leitner et al. PLoS Pathogens
- Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas
- (2012) Muhammad Baghdadi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies
- (2012) I. Verbrugge et al. CANCER RESEARCH
- Antigen-specific Immunotherapy in Ovarian Cancer and p53 as Tumor Antigen
- (2012) Renee Vermeij et al. CURRENT PHARMACEUTICAL DESIGN
- Elafin selectively regulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis
- (2012) Huafeng Wei et al. GYNECOLOGIC ONCOLOGY
- Silencing of the TGF-β1 Gene Increases the Immunogenicity of Cells From Human Ovarian Carcinoma
- (2012) Huafeng Wei et al. JOURNAL OF IMMUNOTHERAPY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy in ovarian cancer
- (2012) Gina M. Mantia-Smaldone et al. Human Vaccines & Immunotherapeutics
- Host CD25+CD4+Foxp3+ Regulatory T Cells Primed by anti-CD137 mAbs Inhibit Graft-versus-Host Disease
- (2011) Juyang Kim et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Prospects for TIM3-Targeted Antitumor Immunotherapy
- (2011) S. F. Ngiow et al. CANCER RESEARCH
- Anti-TIM3 Antibody Promotes T Cell IFN- -Mediated Antitumor Immunity and Suppresses Established Tumors
- (2011) S. F. Ngiow et al. CANCER RESEARCH
- Emerging Tim-3 functions in antimicrobial and tumor immunity
- (2011) Kaori Sakuishi et al. TRENDS IN IMMUNOLOGY
- Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ
- (2010) Juan Dubrot et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immunotherapy for Ovarian Cancer: What's Next?
- (2010) Lana E. Kandalaft et al. JOURNAL OF CLINICAL ONCOLOGY
- Tim-3/Galectin-9 Pathway: Regulation of Th1 Immunity through Promotion of CD11b+Ly-6G+ Myeloid Cells
- (2010) V. Dardalhon et al. JOURNAL OF IMMUNOLOGY
- Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies
- (2010) Paolo A. Ascierto et al. SEMINARS IN ONCOLOGY
- Circulating Mesothelin Protein and Cellular Antimesothelin Immunity in Patients with Pancreatic Cancer
- (2009) F. Mc. Johnston et al. CLINICAL CANCER RESEARCH
- Immune regulation by 4-1BB and 4-1BBL: complexities and challenges
- (2009) Chao Wang et al. IMMUNOLOGICAL REVIEWS
- Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy
- (2009) Y. H. Kim et al. MOLECULAR CANCER THERAPEUTICS
- Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice
- (2008) James O. McNamara et al. JOURNAL OF CLINICAL INVESTIGATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now